Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Enzyme immunoassay

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Enzyme immunoassay. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-004435-31 Sponsor Protocol Number: MVC116278 Start Date*: 2012-05-15
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016480-11 Sponsor Protocol Number: 2009HD/01 Start Date*: 2009-12-28
    Sponsor Name:P Pierre Dellamonica
    Full Title: “No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected b...
    Medical condition: HIV naïve patients, CCR5 tropism, with CD4 > 200/mm3 and HIV RNA < 100 000 copy/ml.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006009-18 Sponsor Protocol Number: TMC278-TiDP15-C221 Start Date*: 2009-04-17
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy.
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2008-008190-58 Sponsor Protocol Number: TMC310911-TiDP21-C201 Start Date*: 2009-04-03
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003484-22 Sponsor Protocol Number: PNC+AHEP Start Date*: 2012-09-11
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly
    Medical condition: 18 years old or older volunteers with general good health
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004617-34 Sponsor Protocol Number: NV20911 Start Date*: 2008-01-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old
    Medical condition: HIV-1 Infection/AIDS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004306-50 Sponsor Protocol Number: A4001050 Start Date*: 2007-04-23
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005063-16 Sponsor Protocol Number: IEO370 Start Date*: 2017-07-17
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A randomized presurgical study with different schedules of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer
    Medical condition: Postmenopausal ER positive breast cancer, waiting for surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002183-26 Sponsor Protocol Number: TMC125-C126 Start Date*: Information not available in EudraCT
    Sponsor Name:Tibotec Pharmaceuticals Ltd
    Full Title: A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000748-14 Sponsor Protocol Number: M06-802 Start Date*: 2006-08-14
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib...
    Medical condition: Antiretroviral experienced, HIV-1 Infection. Adequate ICD classification code not available.
    Disease: Version SOC Term Classification Code Term Level
    9.0 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000712-27 Sponsor Protocol Number: TMC125-C229 Start Date*: 2005-07-15
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008655-42 Sponsor Protocol Number: TMC125VIR2038 Start Date*: 2009-03-31
    Sponsor Name:Janssen Cilag International
    Full Title: A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combinat...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) AT (Completed) DE (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007086-21 Sponsor Protocol Number: TMC125-TiDP35-C213 Start Date*: 2009-01-23
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) FR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004225-26 Sponsor Protocol Number: GS-US-183-0145 Start Date*: 2008-08-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Backgrou...
    Medical condition: Human Innunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003835-28 Sponsor Protocol Number: APHP210089 Start Date*: 2022-02-17
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS
    Full Title: Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ” VANCALLO
    Medical condition: Patients hospitalized for an allogeneic hematopoietic stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004865 10059044 Allogeneic peripheral hematopoietic stem cell transplant LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013657-14 Sponsor Protocol Number: AI438006 Start Date*: 2009-11-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003917-29 Sponsor Protocol Number: GS-US-183-0152 Start Date*: 2008-11-11
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents
    Medical condition: Human Innunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003995-21 Sponsor Protocol Number: ERRADVIH-01 Start Date*: 2007-12-03
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
    Full Title: Estudio piloto del efecto de un antagonista de co-receptores CCR5 sobre la latencia y el reservorio del VIH-1 en pacientes que reciben tratamiento antirretroviral de gran actividad
    Medical condition: VIH
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003354-28 Sponsor Protocol Number: GS-UK-177-0109 Start Date*: 2008-02-19
    Sponsor Name:Gilead Sciences Limited
    Full Title: A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Onc...
    Medical condition: Adult, HIV-1 infected, tenofovir DF- and emtricitabine-naive subjects on a stable HAART regimen of Kivexa (abacavir/lamivudine) and efavirenz, with raised total fasting cholesterol
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002045-23 Sponsor Protocol Number: GS-US-180-0104 Start Date*: 2008-07-18
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects.
    Medical condition: Antiretroviral treatment–naive subjects chronically infected with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 13:40:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA